UK Markets close in 4 hrs 37 mins
Cryptocurrency:

What is dogeday 4/20?

The joke cryptocurrency token dogecoin rallied as fans celebrated online

Coronation Street Soap Scoop! Leanne forced to sell drugs

Coming up on Coronation Street... Leanne tries to repay Simon's debt to Harvey.

Latest stories

  • Millie Mackintosh says there’s so much pressure on new mums to 'bounce back' after pregnancy

    The former reality TV star was addressing the challenges women face during pregnancy and after giving birth.

  • Tens of thousands applied to register to vote on election deadline day

    Around a third of applications were from people under the age of 25.

  • Tumore rene, ok Ue a nuova associazione a base di immunoterapico in prima linea

    Via libera della Commissione europea all'anticorpo monoclonale nivolumab, un farmaco immunoterapico, in associazione con cabozantinib per il trattamento in prima linea di pazienti adulti con carcinoma a cellule renali (Rcc) avanzato. Lo annuncia l'americana Bristol Myers Squibb (Bms), ricordando che "sono due le terapie a base di nivolumab ora autorizzate per il trattamento in prima linea di pazienti con Rcc avanzato nell'Unione europea: nivolumab più ipilimumab nella malattia a rischio intermedio o sfavorevole, e nivolumab in associazione con cabozantinib, approvata indipendentemente dalla categoria di rischio". La decisione della Commissione Europea - spiega Bms in una nota - si basa sui risultati dello studio di fase 3 CheckMate-9ER, che ha dimostrato una superiore efficacia di nivolumab in associazione con cabozantinib rispetto a sunitinib per i 3 endpoint chiave: la sopravvivenza libera da progressione, endpoint primario, il tasso di risposta obiettiva e la sopravvivenza globale. L'associazione nivolumab-cabozantinib è stata ben tollerata, con un profilo di sicurezza che riflette quello noto di entrambi i medicinali, e un basso tasso di eventi avversi correlati al trattamento che hanno portato ad interruzione della terapia. "Con questa approvazione, possiamo ora offrire ai pazienti due diverse associazioni a base di nivolumab che hanno dimostrato significativi benefici di sopravvivenza rispetto a sunitinib - dichiara Dana Walker, vice president, development program lead, genitourinary cancers Bms - Il traguardo odierno si somma al nostro patrimonio di ricerca volto a sviluppare e rendere disponibili nuovi trattamenti per i pazienti con carcinoma a cellule renali avanzato, dapprima con l'unica opzione a base di due immunoterapici, nivolumab più ipilimumab, e ora con un nuovo regime che associa l'immunoterapia con un inibitore della tirosin-chinasi. Siamo pronti a collaborare con un ampio gruppo di stakeholder europei per offrire nivolumab in associazione con cabozantinib ai pazienti che possono beneficiare di questo trattamento". "L'associazione nivolumab-cabozantinib combina due agenti comprovati nel carcinoma a cellule renali avanzato, che insieme hanno mostrato una superiore efficacia per gli endpoint chiave e i sottogruppi di pazienti rispetto a sunitinib nello studio CheckMate-9ER - afferma Marc-Oliver Grimm, professor of medicine and urology department head, Jena University Hospital - Inoltre, il profilo di sicurezza dell'associazione è risultato maneggevole con i protocolli noti, portando a un basso tasso di interruzioni correlate al trattamento. Con l'approvazione odierna, i clinici in tutta l'Unione europea saranno in grado di offrire ai pazienti con Rcc avanzato un'ulteriore terapia di associazione che può aiutarli a ottenere un controllo precoce della malattia e migliorare gli esiti di sopravvivenza". Nivolumab in associazione con cabozantinib - prosegue la nota - è stato approvato contro l'Rcc nell'Unione europea con un regime flessibile di dosaggio, ossia la possibilità di utilizzare nivolumab 240 mg somministrato per via endovenosa ogni 2 settimane, oppure nivolumab 480 mg somministrato per via endovenosa ogni 4 settimane, in associazione con cabozantinib 40 mg somministrato una volta al giorno per via orale. Oltre che in Ue, l'associazione di nivolumab con cabozantinib è stata approvata a gennaio 2021 per il trattamento di prima linea del carcinoma a cellule renali avanzato dalla Food and Drug Administration negli Stati Uniti, e ulteriori domande di registrazione sono in valutazione da parte di altre agenzie regolatorie in tutto il mondo. I risultati dello studio CheckMate-9ER sono stati pubblicati nel 'New England Journal of Medicine' nel marzo scorso. "Con i progressi della ricerca, i pazienti convivono più a lungo che in passato con il tumore del rene avanzato e quindi è diventato sempre più importante considerare come il trattamento influisce sulla vita di tutti i giorni - commenta Rachel Giles, International Kidney Cancer Coalition - Siamo lieti di vedere l'approvazione di una nuova associazione di prima linea per i pazienti con carcinoma a cellule renali avanzato, che ha il potenziale non solo di controllare il tumore, ma anche di mantenere la loro qualità di vita correlata allo stato di salute".

  • Global Urolithiasis Management Devices Market to Reach $2.1 Billion by 2027

    Abstract: - Global Urolithiasis Management Devices Market to Reach $2. 1 Billion by 2027. - Amid the COVID-19 crisis, the global market for Urolithiasis Management Devices estimated at US$1.New York, April 20, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Urolithiasis Management Devices Industry" - https://www.reportlinker.com/p06033203/?utm_source=GNW 5 Billion in the year 2020, is projected to reach a revised size of US$2.1 Billion by 2027, growing at a CAGR of 4.6% over the analysis period 2020-2027. Extracorporeal Shock Wave Lithotripsy (ESWL), one of the segments analyzed in the report, is projected to record a 4.4% CAGR and reach US$842.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Intracorporeal Lithotripsy segment is readjusted to a revised 4.9% CAGR for the next 7-year period. - The U.S. Market is Estimated at $416.7 Million, While China is Forecast to Grow at 7.4% CAGR - The Urolithiasis Management Devices market in the U.S. is estimated at US$416.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$437.9 Million by the year 2027 trailing a CAGR of 7.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 3.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR. - Percutaneous Nephrolithotomy Segment to Record 4.6% CAGR - In the global Percutaneous Nephrolithotomy segment, USA, Canada, Japan, China and Europe will drive the 4.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$254.8 Million in the year 2020 will reach a projected size of US$343.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$283.1 Million by the year 2027, while Latin America will expand at a 5% CAGR through the analysis period. - Select Competitors (Total 42 Featured) - Boston ScientificCook MedicalCybersonicsDirexgroupDornierDornierElmedKarl StorzMTS MedicalOlympus Read the full report: https://www.reportlinker.com/p06033203/?utm_source=GNW I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Urolithiasis Management Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Urolithiasis Management Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Urolithiasis Management Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Extracorporeal Shock Wave Lithotripsy (ESWL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Extracorporeal Shock Wave Lithotripsy (ESWL) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Extracorporeal Shock Wave Lithotripsy (ESWL) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Intracorporeal Lithotripsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Intracorporeal Lithotripsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Intracorporeal Lithotripsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Percutaneous Nephrolithotomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Percutaneous Nephrolithotomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Percutaneous Nephrolithotomy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Ambulatory Surgical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 20: World Historic Review for Ambulatory Surgical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 21: World 15-Year Perspective for Ambulatory Surgical Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Table 22: USA Current & Future Analysis for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 23: USA Historic Review for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 24: USA 15-Year Perspective for Urolithiasis Management Devices by Treatment Type - Percentage Breakdown of Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types for the Years 2012, 2020 & 2027 Table 25: USA Current & Future Analysis for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 26: USA Historic Review for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 27: USA 15-Year Perspective for Urolithiasis Management Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027 CANADA Table 28: Canada Current & Future Analysis for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 29: Canada Historic Review for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 30: Canada 15-Year Perspective for Urolithiasis Management Devices by Treatment Type - Percentage Breakdown of Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types for the Years 2012, 2020 & 2027 Table 31: Canada Current & Future Analysis for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 32: Canada Historic Review for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 33: Canada 15-Year Perspective for Urolithiasis Management Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027 JAPAN Table 34: Japan Current & Future Analysis for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 35: Japan Historic Review for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 36: Japan 15-Year Perspective for Urolithiasis Management Devices by Treatment Type - Percentage Breakdown of Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types for the Years 2012, 2020 & 2027 Table 37: Japan Current & Future Analysis for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 38: Japan Historic Review for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 39: Japan 15-Year Perspective for Urolithiasis Management Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027 CHINA Table 40: China Current & Future Analysis for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 41: China Historic Review for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 42: China 15-Year Perspective for Urolithiasis Management Devices by Treatment Type - Percentage Breakdown of Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types for the Years 2012, 2020 & 2027 Table 43: China Current & Future Analysis for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 44: China Historic Review for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 45: China 15-Year Perspective for Urolithiasis Management Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027 EUROPE Table 46: Europe Current & Future Analysis for Urolithiasis Management Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 47: Europe Historic Review for Urolithiasis Management Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 48: Europe 15-Year Perspective for Urolithiasis Management Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 49: Europe Current & Future Analysis for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 50: Europe Historic Review for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 51: Europe 15-Year Perspective for Urolithiasis Management Devices by Treatment Type - Percentage Breakdown of Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types for the Years 2012, 2020 & 2027 Table 52: Europe Current & Future Analysis for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 53: Europe Historic Review for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 54: Europe 15-Year Perspective for Urolithiasis Management Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027 FRANCE Table 55: France Current & Future Analysis for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 56: France Historic Review for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 57: France 15-Year Perspective for Urolithiasis Management Devices by Treatment Type - Percentage Breakdown of Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types for the Years 2012, 2020 & 2027 Table 58: France Current & Future Analysis for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 59: France Historic Review for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 60: France 15-Year Perspective for Urolithiasis Management Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027 GERMANY Table 61: Germany Current & Future Analysis for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 62: Germany Historic Review for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 63: Germany 15-Year Perspective for Urolithiasis Management Devices by Treatment Type - Percentage Breakdown of Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types for the Years 2012, 2020 & 2027 Table 64: Germany Current & Future Analysis for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 65: Germany Historic Review for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 66: Germany 15-Year Perspective for Urolithiasis Management Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027 ITALY Table 67: Italy Current & Future Analysis for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 68: Italy Historic Review for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 69: Italy 15-Year Perspective for Urolithiasis Management Devices by Treatment Type - Percentage Breakdown of Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types for the Years 2012, 2020 & 2027 Table 70: Italy Current & Future Analysis for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 71: Italy Historic Review for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 72: Italy 15-Year Perspective for Urolithiasis Management Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 73: UK Current & Future Analysis for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 74: UK Historic Review for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 75: UK 15-Year Perspective for Urolithiasis Management Devices by Treatment Type - Percentage Breakdown of Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types for the Years 2012, 2020 & 2027 Table 76: UK Current & Future Analysis for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 77: UK Historic Review for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 78: UK 15-Year Perspective for Urolithiasis Management Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027 SPAIN Table 79: Spain Current & Future Analysis for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 80: Spain Historic Review for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 81: Spain 15-Year Perspective for Urolithiasis Management Devices by Treatment Type - Percentage Breakdown of Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types for the Years 2012, 2020 & 2027 Table 82: Spain Current & Future Analysis for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 83: Spain Historic Review for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 84: Spain 15-Year Perspective for Urolithiasis Management Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027 RUSSIA Table 85: Russia Current & Future Analysis for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 86: Russia Historic Review for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 87: Russia 15-Year Perspective for Urolithiasis Management Devices by Treatment Type - Percentage Breakdown of Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types for the Years 2012, 2020 & 2027 Table 88: Russia Current & Future Analysis for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 89: Russia Historic Review for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 90: Russia 15-Year Perspective for Urolithiasis Management Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027 REST OF EUROPE Table 91: Rest of Europe Current & Future Analysis for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 92: Rest of Europe Historic Review for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 93: Rest of Europe 15-Year Perspective for Urolithiasis Management Devices by Treatment Type - Percentage Breakdown of Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types for the Years 2012, 2020 & 2027 Table 94: Rest of Europe Current & Future Analysis for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 95: Rest of Europe Historic Review for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 96: Rest of Europe 15-Year Perspective for Urolithiasis Management Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 97: Asia-Pacific Current & Future Analysis for Urolithiasis Management Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR Table 98: Asia-Pacific Historic Review for Urolithiasis Management Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 99: Asia-Pacific 15-Year Perspective for Urolithiasis Management Devices by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 Table 100: Asia-Pacific Current & Future Analysis for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 101: Asia-Pacific Historic Review for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 102: Asia-Pacific 15-Year Perspective for Urolithiasis Management Devices by Treatment Type - Percentage Breakdown of Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types for the Years 2012, 2020 & 2027 Table 103: Asia-Pacific Current & Future Analysis for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 104: Asia-Pacific Historic Review for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 105: Asia-Pacific 15-Year Perspective for Urolithiasis Management Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027 AUSTRALIA Table 106: Australia Current & Future Analysis for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 107: Australia Historic Review for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 108: Australia 15-Year Perspective for Urolithiasis Management Devices by Treatment Type - Percentage Breakdown of Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types for the Years 2012, 2020 & 2027 Table 109: Australia Current & Future Analysis for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 110: Australia Historic Review for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 111: Australia 15-Year Perspective for Urolithiasis Management Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgical Centers for the Years 2012, 2020 & 2027 INDIA Table 112: India Current & Future Analysis for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR Table 113: India Historic Review for Urolithiasis Management Devices by Treatment Type - Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR Table 114: India 15-Year Perspective for Urolithiasis Management Devices by Treatment Type - Percentage Breakdown of Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment Types for the Years 2012, 2020 & 2027 Table 115: India Current & Future Analysis for Urolithiasis Management Devices by End-Use - Hospitals & Clinics and Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: https://www.reportlinker.com/p06033203/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • Velodyne Lidar Signs Multi-Year Sales Agreement with Gatik

    Velodyne Lidar announced a multi-year sales agreement with Gatik, which automates on-road transportation networks for B2B middle mile logistics.

  • Global Opioids Market Trajectory & Analytics Report 2021-2027 Featuring Egalet, Janssen Pharma, Pfizer, Purdue Pharma, Sanofi, Sun Pharma, West-Ward Pharma

    Dublin, April 20, 2021 (GLOBE NEWSWIRE) -- The "Opioids - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Opioids Market to Reach $31.9 Billion by 2027Amid the COVID-19 crisis, the global market for Opioids estimated at US$25.4 Billion in the year 2020, is projected to reach a revised size of US$31.9 Billion by 2027, growing at a CAGR of 3.3% over the period 2020-2027. Immediate-Release/Short-Acting Opioid, one of the segments analyzed in the report, is projected to record 2.5% CAGR and reach US$16 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Extended-Release/Long-Acting Opioid segment is readjusted to a revised 4.1% CAGR for the next 7-year period.The U.S. Market is Estimated at $6.9 Billion, While China is Forecast to Grow at 5.9% CAGRThe Opioids market in the U.S. is estimated at US$6.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2027 trailing a CAGR of 5.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1% and 2.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.Select Competitors (Total 31 Featured): Egalet CorporationJanssen Pharmaceuticals, Inc.Pfizer, Inc.Purdue Pharma LPSanofiSun Pharmaceutical Industries Ltd.West-Ward Pharmaceuticals Corporation Key Topics Covered: I. METHODOLOGYII. EXECUTIVE SUMMARY1. MARKET OVERVIEW Influencer Market InsightsWorld Market TrajectoriesImpact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS4. GLOBAL MARKET PERSPECTIVEIII. MARKET ANALYSIS United StatesCanadaJapanChinaEuropeFranceGermanyItalyUnited KingdomSpainRussiaRest Of EuropeAsia-PacificAustraliaIndiaSouth KoreaRest Of Asia-PacificLatin AmericaArgentinaBrazilMexicoRest Of Latin AmericaMiddle EastIranIsraelSaudi ArabiaUnited Arab EmiratesRest Of Middle EastAfrica IV. COMPETITION Total Companies Profiled: 31 For more information about this report visit https://www.researchandmarkets.com/r/doz5w6 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

  • Asda takeover could lead to higher petrol prices, warns competition watchdog

    The CMA said a probe raised ‘local competition concerns in relation to the supply of road fuel in 36 areas across the UK’.

  • Laschet wins battle to lead Merkel's party into German election

    Armin Laschet, the governor of Germany’s most populous state, on Tuesday won a bruising power struggle to become the candidate of Chancellor Angela Merkel’s center-right bloc for chancellor in the September election. Laschet, 60, now faces another big battle: to connect with voters and win over frustrated fellow conservatives who backed his more popular rival, Markus Soeder.Their Union bloc is the last major political force to nominate a candidate for chancellor in the Sept. 26 parliamentary election, in which Merkel is not seeking a fifth term after nearly 16 years in power.The race turned into a heated duel after both Laschet, the leader of Merkel’s Christian Democratic Union, and Soeder, who leads its smaller Bavarian sister party, the Christian Social Union, declared their interest in succeeding Merkel.“The die is cast: Armin Laschet will be the chancellor candidate of the Union,” Soeder said on Tuesday. “We will support him with all our strength, without a grudge."Parts of the CDU favored Soeder, while others vehemently opposed his bid to elbow Laschet aside for the top job. Soeder has much better poll ratings, but Laschet was elected in January as the leader of by far the bigger of the sister parties. It was primarily a conflict of personality and style rather than policy.Laschet is the governor of the western state of North Rhine-Westphalia. Soeder is the governor of Bavaria.At the beginning of last week, Laschet informally rallied the CDU leadership behind his bid. But Soeder said the matter shouldn’t be resolved “only in a small back room.”After days of talks failed to produce a solution but laid bare deep divisions in the CDU, Soeder said Monday that the bigger party must decide the matter and his CSU would respect a “clear decision.”At a turbulent meeting of the CDU leadership that lasted until after midnight, 31 of its members voted for Laschet, nine for Soeder and six abstained, news agency dpa reported. That prompted Soeder to concede.The Union bloc campaigns together in federal elections and has a joint parliamentary group in Berlin. The CSU exists only in Bavaria, while the CDU runs in Germany’s other 15 states.The Union leads polls ahead of the environmentalist Greens, who on Monday nominated Annalena Baerbock as their first candidate to be chancellor. The struggling center-left Social Democrats nominated Finance Minister Olaf Scholz as their candidate months ago.(AP)

  • XP POWER LTD - Result of Annual General Meeting

    20 April 2021

  • Global NGS Sample Preparation Market Industry Analysis, Size, Share, Growth, Trends, and Forecasts to 2030 - ResearchAndMarkets.com

    The "NGS Sample Preparation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

  • Cutting greenhouse gas emissions – and the lifestyle changes needed

    The Government plans to cut emissions by 78% by 2035 to tackle climate change.

  • Global Eco-Friendly Bitumen Markets, 2020-2021 & 2025 - Focus on Applications, Products, Grades, Patent Analysis, and Country Analysis - ResearchAndMarkets.com

    The "Eco-Friendly Bitumen Market - A Global Market and Regional Analysis: Focus on Applications, Products, Grades, Patent Analysis, and Country Analysis - Analysis and Forecast, 2020-2025" report has been added to ResearchAndMarkets.com's offering.

  • Superlega, Nino D'Angelo: "Si facciano campionato per ricchi, quello non è calcio"

    "A me interessa che non ci sia il Napoli, in quella superlega: si facessero il loro campionato per ricchi, tanto ce li hanno i soldi. Noi dobbiamo stabilire se il calcio è ancora passione o è diventato solo business. Perché se è solo business, a un tifoso vero non interessa". Nino D'Angelo non ci sta, e da super tifoso del suo Napoli dice la sua all'Adnkronos sulla nascita della nuova superlega europea a cui parteciperanno, allo stato attuale, i tre club italiani Inter, Milan e Juventus. "Per un tifoso -affonda l'attore e cantante partenopeo- non è bello sentire queste notizie. Le differenze nel calcio non dovrebbero esistere. Il calcio è una passione bellissima, lo vogliono rovinare a tutti i costi e secondo me, sono proprio i tifosi di quelle squadre, Inter, Milan e Juve, che dovrebbero ribellarsi". "Coi soldi si fa tutto ma io ho paura dei potenti, di quelli che hanno troppi soldi -spiega D'Angelo- Per me il calcio è sentimento, io sono un passionale, io ho pianto per Maradona ma ora è davvero cambiato il mondo. I soldi con la passione non ci azzeccano nulla". L'artista napoletano aggiunge poi una considerazione: "Io sono tifoso del Napoli perché sono tifoso della mia città, il calcio è amore. E dovrebbero stare attenti perché il calcio ha bisogno del tifoso, è come quando uno ama e l'altro non ama: tra il pubblico e la squadra è una storia d'amore. Il calcio ha bisogno del pubblico, per amore ma anche per i soldi. Se il pubblico si disaffeziona, poi chi paga più il biglietto per andare allo stadio?". Questi grossi club "sono sicuramente belli a vedersi, ma così facendo si fanno un campionato loro. Se ce la fanno, è finito il calcio. Allora la Coppa dei Campioni, la Coppa Uefa cosa ci stanno a fare? Bisogna vedere e sperare che gli altri grandi club si rifiutino, così restano fuori dal sistema. Alla fine, bisogna vedere se il sistema calcio vince sulla passione vera".

  • Luxury homes left teetering over cliff after Wales beach landslide

    A huge landslide has slid on to a beach in north Wales, leaving homes teetering on the edge of a cliff. Luxury houses have been left in a precarious position over the beach at Nefyn, near Pwllheli. The landslide on Monday pulled large parts of cliff-top gardens and even a wooden bench on to the shore.

  • This game-changing SPF has improved my skin in just one week

    If a suncream can ever be cool, let me tell you, this is it.

  • The AZEK® Company Inc. Announces Fiscal Second Quarter 2021 Earnings Release and Investor Conference Call on May 13, 2021

    The AZEK® Company Inc. Announces Fiscal Second Quarter 2021 Earnings Release and Investor Conference Call on May 13, 2021

  • BWXT Announces $2.2 Billion in Contracts for Naval Nuclear Reactor Components and Fuel

    @BWXTech Announces $2.2 Billion in Contracts for Naval Nuclear Reactor Components and Fuel

  • Brexit news – live: Johnson pledges end to NI trade barriers as watchdog says PM ‘should not rule on sleaze’

    Follow all the latest developments

  • Everton accuse ‘Big Six’ of ‘preposterous arrogance’ over ESL plan

    The proposal has attracted widespread condemnation .

  • Investors turn to growth stocks' results after strong earnings start

    On the heels of blockbuster earnings from major U.S. banks, investors are focused on whether an upcoming batch of earnings from major technology-related companies can sustain the season's early momentum. Estimated year-over-year first-quarter earnings growth for S&P 500 companies rose to 31% from 25% in the past week, based on Refinitiv data, driven by last week's stronger-than-expected results from Wells Fargo & Co, Goldman Sachs Group Inc and other banks. Tuesday brings results from stay-at-home winner Netflix Inc, which is part of the FAANG group of high-profile tech-related names.